[Stock Analysis] Memo | Challenge to 2028: (4519) Chugai Pharmaceutical's 'Medicine of the Future' and the Promising Obesity Drug
Hello, this is Pheue.
Thank you for always reading my articles.
When flipping through the Japan Company Handbook, there is one company that catches the eye with its exceptionally brilliant profit margins and a strategy focused on the 'world.' That company is Chugai Pharmaceutical (4519).
This time, looking toward the near future of 2028, I have delved into what kind of surprising new drugs this company is preparing, focusing especially on the highly anticipated 'next-generation obesity treatment.'
I have also posted a video on YouTube about Chugai Pharmaceutical's challenge toward 2028, so I would be happy if you could watch it when you have time.
1: Why this stock caught my attention
It was the 'obesity treatment' that has been a hot topic in the news recently. Demand is exploding worldwide, but at the same time, I hear about issues like 'muscle loss' and 'rebound after stopping.' Amidst this, I learned that Chugai Pharmaceutical is developing a groundbreaking new drug with an approach to 'lose weight while protecting muscle,' and I was convinced that 'this is exactly what many people have been waiting for,' so I decided to look into it in detail.
2: Summary of the business model
It is a 'research and development-oriented company that creates innovative pharmaceuticals one after another, armed with world-class drug discovery technology.'
Partnership with the Swiss giant Roche: They have formed the strongest tag team, where they sell Roche's powerful drugs in Japan and deliver the groundbreaking drugs created by Chugai to the world through Roche.
Proprietary 'antibody technology': Chugai possesses advanced biotechnology that only they can perform, which supports their phenomenal profit margins (among the top class even for Japanese companies!).
3: Highlights from the Japan Company Handbook and newspapers
The focus points for Chugai Pharmaceutical toward '2028,' especially the obesity drug 'GYM329' currently under development, are amazing.
Next-generation obesity drug that 'protects muscle' (GYM329): This is a new drug that suppresses the action of proteins that cause muscle atrophy. By using it in combination with currently mainstream drugs, it is expected to have dream-like effects such as 'reducing fat while maintaining muscle mass' and 'preventing rebound.'
Toward approval application in 2028: According to reports from the Nikkei and other newspapers, the goal is to file for approval for this 'GYM329' as early as 2028.
A new weapon called 'mid-sized molecules': They are aiming to be the world leader in 'mid-sized molecule' pharmaceuticals, which take the 'best of both worlds' from conventional drugs and biopharmaceuticals, and this could become a major pillar of their earnings by 2028.
4: My personal excitement point: 'Future potential'
What I am most excited about is a future where science supports us in living healthily and beautifully.
If a drug like 'GYM329' is put into practical use, it can be expected to be used in a wider range of fields, such as measures against frailty (muscle weakness) in the elderly, rather than just losing weight. Thinking that Chugai Pharmaceutical might rewrite the common sense of 'obesity treatment' worldwide by 2028 makes me want to watch over its growth as an investor.
5: A Beginner's Realistic Assessment
Pharmaceutical stocks carry the risk of significant volatility depending on development progress (clinical trial results).
Current Stance: This is a stock I want to hold onto carefully as an 'investment in the future,' looking 10 to 20 years ahead.
Action Plan: I plan to keep a very close eye on how the progress of the pipeline (new drug candidates), including 'GYM329,' is described in the Spring issue of the Japan Company Handbook in March!
#Investment #JapaneseStocks #AssetManagement #InvestmentBeginner #ChugaiPharmaceutical #StockAnalysis #GYM329 #ObesityTreatment #Memorandum #FutureOfHealth
